NDA 022402 · Hikma
Codeine Sulfate
Codeine Sulfate · Oral
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 16, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
511
100 Phase 3, 26 recruiting
FAERS reports
3,309
2,121 serious, 799 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF CODEINE SULFATE TABLETS Addiction, Abuse, and Misuse Because the use of Codeine Sulfate Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 ), Dosage and Administration ( 2.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Codeine Sulfate Tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Codeine Sulfate Tablets are essential [see Warnings and Precautions ( 5.2 )] . Accidental Ingestion Accidental ingestion of...
What it is approved for
From the label in effect Dec 22, 2025.
Codeine Sulfate Tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Limitations of Use: • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )] , reserve opioid analgesics, including Codeine Sulfate Tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Codeine Sulfate Tablets are an opioid agonist, indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. ( 1 ) Limitations of Use • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Codeine Sulfate Tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )
Mechanism: Codeine sulfate is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine, although the exact mechanism of analgesic action remains unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 16, 2009 Original approval · Type 7 - Drug Already Marketed without Approved NDA ReviewREMSSummary Review
3 products under this application
- CODEINE SULFATE · CODEINE SULFATE 60MG · TABLET, ORAL · Prescription · TE AB
- CODEINE SULFATE · CODEINE SULFATE 15MG · TABLET, ORAL · Prescription · TE AB
- CODEINE SULFATE · CODEINE SULFATE 30MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Codeine" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Opioid Prescription After Cesarean TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT04296396 · 5,521 participants · Start Sep 21, 2020 · Primary completion Apr 7, 2022
Drug: 0 to 20 tablets of oxycodone 5mg; Fixed opioid prescription · For: Pregnancy Related; Opioid Use; Pain
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Paracetamol Vs Caffeine Vs Codeine in the Management of Post Traumatic Pain in EmergenciesPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT05229965 · 1,500 participants · Start Nov 1, 2022 · Primary completion Jun 27, 2023
Drug: Paracetamol; Paracetamol Codeine and 1 more · For: Acute Pain Due to Trauma
Sites: Monastir, Tunisia
- Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Post-operative PainPivotal-lookingNot yet recruiting
Ailin LuoAcademic, hospital or other
NCT06721988 · 1,316 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2026
Drug: oxycodone and parecoxib sodium combinations; Placebo and parecoxib sodium combinations · For: Oxycodone; Chronic Pain, Postoperative
- Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back PainPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02883569 · 1,102 participants · Start Sep 2016 · Primary completion Dec 2020
Drug: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac; codeine, oxycontine, IRcodone, Tramadol · For: Low Back Pain
Sites: Seoul, South Korea
- Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainPivotal-lookingCompleted
Purdue Pharma LPIndustry
NCT01358526 · 1,095 participants · Start May 2011 · Primary completion Oct 2012
Drug: Oxycodone/Naloxone Controlled-release; Placebo · For: Low Back Pain
Sites: Birmingham, Alabama; Haleyville, Alabama; Huntsville, Alabama · 151 sites in all
- Tapentadol (CG5503)Pivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00421928 · 1,030 participants · Start Jan 2007 · Primary completion Jul 2008
Drug: oxycodone; placebo and 1 more · For: Osteoarthritis, Knee; Pain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity817
- nausea506
- drug ineffective400
- malaise380
- vomiting373
- headache371
- arthralgia363
- diarrhoea352
- dyspnoea338
- fatigue310
- cough309
- pain286
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 21 |
| 2010 | 233 |
| 2011 | 387 |
| 2012 | 501 |
| 2013 | 154 |
| 2014 | 232 |
| 2015 | 102 |
| 2016 | 122 |
| 2017 | 144 |
| 2018 | 156 |
| 2019 | 243 |
| 2020 | 154 |
| 2021 | 120 |
| 2022 | 200 |
| 2023 | 140 |
| 2024 | 201 |
| 2025 | 131 |
| 2026 | 58 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Codeine Sulfate (Codeine Sulfate)
2024 spending
$975K
Beneficiaries
3,876
14,814 claims
Per beneficiary
$252
$0.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,157,073 |
| 2021 | $1,295,086 |
| 2022 | $1,271,668 |
| 2023 | $1,122,751 |
| 2024 | $975,101 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pain Relief with Combination Acetaminophen/Codeine or Ibuprofen following Third-Molar Extraction: A Systematic Review and Meta-Analysis.
Watson H, Hildebolt C, Rowland K · Pain Med 2022 · Meta-Analysis, Systematic Review
- Tramadol with or without paracetamol (acetaminophen) for cancer pain.
Wiffen PJ, Derry S, Moore RA · Cochrane Database Syst Rev 2017 · Meta-Analysis, Systematic Review
- Steroid use after pediatric tonsillectomy: A systematic review and meta-analysis.
Puyo EM, Chen JL, Mullick R, et al. · Int J Pediatr Otorhinolaryngol 2025 · Meta-Analysis, Systematic Review
- Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.
Nielsen S, Sabioni P, Trigo JM, et al. · Neuropsychopharmacology 2017 · Meta-Analysis, Systematic Review
- Efficacy of Truncal Plane Blocks in Pediatric Patients Undergoing Subcutaneous Implantable Cardioverter-Defibrillator Placement.
Zhang Y, Gong H, Zhan B, et al. · J Cardiothorac Vasc Anesth 2021 · Randomized Controlled Trial
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.